[1] 黄从新, 张澎, 黄德嘉, 等.心房颤动:目前的认识和治疗建议-2015[J].中国心脏起搏与心电生理杂志, 2015, 29(5): 377-434. [2] 中华心血管病杂志血栓循证工作组.非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议[J].中华心血管病杂志, 2014, 42(5): 362-369. [3] Liu T, Hui J, Hou Y, et a1.Meta-analysis of efficacy and safety of low-intensity warfarin therapy for east asian patients with nonvalvular atrial fibrillation[J].Am J Cardiol, 2017, 120(9): 1562-1567. [4] 文力, 韩兴, 周浩, 等.新型口服抗凝药物达比加群和利伐沙班相关出血的应对[J].中国药物警戒, 2014, 11(1): 15-18. [5] 中华心血管病杂志编辑委员会血栓栓塞防治循证工作组.达比加群酯用于非瓣膜病心房颤动患者卒中预防的临床应用建议[J].中华心血管病杂志, 2014, 42(3): 188-192. [6] 张澍, 杨艳敏, 黄从新, 等.中国心房颤动患者卒中预防规范[J].中华心律失常学杂志, 2015, 19(3): 162-173. [7] 王志尊, 王伟, 杜昕, 等.非瓣膜病心房颤动患者华法林长期抗凝治疗的依从性[J].中华心血管病杂志, 2017, 45(11): 920-923. [8] 娄莹, 刘红, 韩璐璐, 等.CYP2C9和VKORC1基因多态性对肺栓塞患者华法林维持剂量的影响[J].中国药物警戒, 2012, 9(4): 202-204. [9] 孙艺红, 胡大一.非瓣膜病心房颤动患者全球抗凝注册研究中国亚组基线数据分析[J].中华心血管病杂志, 2014, 42(10): 846-850. [10] 吴章薇, 梅丽平, 赵军, 等.心房颤动合并脑栓塞患者的抗凝治疗现状和出血转化分析[J].中国卒中杂志, 2016, 11(1): 47-53. [11] Connolly J, Ezekowitz M, Yusuf S, et a1.Newly identified events in the RE-LY trial[J].New Engl J Med, 2010, 363(19): 1875-1876. [12] Heidbuchel H, Verhamme P, Alings M, et a1. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J].Europace, 2013, 15(5): 625-651. [13] Eikelboom J, Wallentin L, Connolly J, et a1.Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial[J].Circulation, 2011, 123(21): 2363-2372. [14] Healey S, Eikelboom J, Douketis J, et a1.Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulant therapy (RE-LY) randomized trial[J]. Circulation, 2012, 126(3): 343-348. [15] Vanryn J, Baruch L, Clemens A, et a1.Interpretation of point-of-care INR results in patients treated with dabigatran[J]. Am J Med, 2012, 125(4): 417-420. |